Literature DB >> 25321178

Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.

Laure Surgers1, Nadia Valin, Céline Viala, Anders Boyd, Laurent Fonquernie, Pierre-Marie Girard, Laurence Morand-Joubert, Jean-Luc Meynard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25321178     DOI： 10.1097/QAI.0000000000000401

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  2 in total

1.  Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Authors:  Marc Foca; Ram Yogev; Andrew Wiznia; Rohan Hazra; Patrick Jean-Philippe; Bobbie Graham; Paula Britto; Vincent J Carey; Jennifer King; Edward P Acosta; Tim R Cressey
Journal:  Pediatr Infect Dis J       Date:  2016-09       Impact factor: 2.129

2.  Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.

Authors:  Nicola Gianotti; Andrea Poli; Silvia Nozza; Vincenzo Spagnuolo; Giuseppe Tambussi; Simona Bossolasco; Paola Cinque; Myriam Maillard; Massimo Cernuschi; Laura Galli; Adriano Lazzarin; Antonella Castagna
Journal:  J Int AIDS Soc       Date:  2015-07-30       Impact factor: 5.396
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.